{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022919","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.750446+00:00","generated_at":"2026-06-22T03:59:12.857543+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PMV Pharma Q3 2022 net loss widens to $54M; cash at $258.9M; PC14586 trial ongoing","bullets":["Net loss for nine months ended Sep 30, 2022: $54.0M vs $39.5M YoY; cash & equivalents $258.9M (Dec 2021: $314.1M).","R&D expenses rose to $37.0M (vs $24.3M) due to PC14586 clinical costs; G&A $18.9M (vs $15.5M).","Enrollment continues in Phase 1/2 PYNNACLE trial of PC14586 for p53 Y220C advanced solid tumors.","Phase 1b combo trial with Merck's KEYTRUDA on track to initiate in Q4 2022.","Appointed Dr. Carol Gallagher to Board; brings 30 years of biotech leadership."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022919","json":"https://secwatch.observer/filing/0000950170-22-022919.json","markdown":"https://secwatch.observer/filing/0000950170-22-022919.md","text":"https://secwatch.observer/filing/0000950170-22-022919.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000095017022022919/0000950170-22-022919-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000095017022022919/pmvp-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:59:12.857543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12df586ab08c309f6e3eee890662ff5591d1bf03","claim":"PMV Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000095017022022919/0000950170-22-022919-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}